MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for developm ...

Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest ...

Molecular Partners and Orano Med expand collaboration to develop ten 212Pb-Radio-DARPin therapy candidates, initiating clinical trials in 2025. Molecular Partners AG and Orano Med have expanded ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight ...

This collaboration between Sanofi, RadioMedix and Orano Med focuses specifically on the late-stage project, AlphaMedixTM (212Pb-DOTAMTATE), which currently is being evaluated for the treatment of ...

Molecular Partners (MOLN) and Orano Med preparing for clinical entry in 2025 “We are very pleased with the results of MP0712, to date. The homogeneous distribution observed through alpha ...

Partnership is expected to develop radioligand therapies based on lead-212 alpha-emitting isotopes, which offer the opportunity to destroy cancer cells with minimal damage to healthy tissue. Sanofi ...

With multiple drugmakers already announcing a slew of radiopharmaceutical moves this year, France’s Orano Med is doubling down on the nuclear medicine craze. Clinical-stage Orano Med—which is ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

“At Orano Med, we are at the forefront of innovation in radioligand therapy and are developing a global industrial platform for the manufacture and distribution of our 212Pb-conjugated drug ...